⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20744797 | 0.84 | — | — | |
| SCHEMBL2826221 | 0.79 | — | — | |
| SCHEMBL2828998 | 0.78 | — | — | |
| SCHEMBL28985069 | 0.78 | — | — | |
| SCHEMBL1665906 | 0.77 | PNP (0.31) | — | |
| SCHEMBL20165 | 0.77 | DHFR (0.33) | — | |
| SCHEMBL2512344 | 0.76 | SUMO1 (0.36) | — | |
| SCHEMBL2938692 | 0.76 | PNP (0.31) | — | |
| SCHEMBL26506 | 0.76 | SUMO1 (0.36) | — | |
| SCHEMBL29512549 | 0.74 | SUMO1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802645-B2 | Molecule for treating an inflammatory disorder | PROSENSA TECHNOLOGIES B.V. (NL) | 2014-08-12 | — | — | US | claimed |
| CN-111448316-B | Novel thiophosphorous acid amides | 罗氏创新中心哥本哈根有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20240271140-A1 | LPA INHIBITOR AND USE THEREOF | CHENGDU XINZHENGHE PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) | 2024-08-15 | — | — | US | disclosed |
| EP-4403633-A1 | LPA INHIBITOR AND USE THEREOF | Genoval Therapeutics Co., Ltd. (CN) | 2024-07-24 | — | — | EP | disclosed |
| CN-118286449-A | Oligomer and oligomer conjugate | 豪夫迈·罗氏有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-114736901-B | Oligonucleotides for reducing PD-L1 expression | 豪夫迈·罗氏有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-114736900-B | Oligonucleotides for reducing PD-L1 expression | 豪夫迈·罗氏有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-112274647-B | Oligomer and oligomer conjugate | 豪夫迈·罗氏有限公司 | 2024-04-23 | — | — | CN | disclosed |
| CN-114085836-B | Oligonucleotides for reducing PD-L1 expression | 豪夫迈·罗氏有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-117441103-A | Novel medical technology using follicular T cells | 国立大学法人大阪大学 | 2024-01-23 | — | — | CN | disclosed |
| WO-2019162487-A1 | METHOD FOR THE SELECTIVE AMPLIFICATION OF NUCLEIC ACIDS AND KIT FOR CARRYING OUT SAME | AGCT GMBH (DE) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019162529-A1 | METHOD FOR PRIMER EXTENSION REACTION WITH IMPROVED SPECIFICITY | AGCT GMBH (DE) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019162478-A1 | METHOD FOR DISPLAYING THE PROGRESS OF THE AMPLIFICATION OF NUCLEIC ACIDS AND KIT FOR CARRYING OUT SAME | AGCT GMBH (DE) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019162530-A1 | AGMETHOD FOR AMPLIFICATION OF A NUCLEIC ACID HAVING IMPROVED SPECIFICITY | AGCT GMBH (DE) | 2019-08-29 | — | — | WO | disclosed |
| EP-2516647-B1 | Molecule for treating an inflammatory disorder | BIOMARIN TECH BV (NL) | 2016-12-14 | — | — | EP | disclosed |
| US-8802645-B2 | Molecule for treating an inflammatory disorder | PROSENSA TECHNOLOGIES B.V. (NL) | 2014-08-12 | — | — | US | disclosed |
| CN-103221055-A | Modulation of TIMP1 and TIMP2 expression | NITTO DENKO CORP | 2013-07-24 | — | — | CN | disclosed |
| EP-2516647-A1 | MOLECULE FOR TREATING AN INFLAMMATORY DISORDER | Prosensa Technologies B.V. (NL) | 2012-10-31 | — | — | EP | disclosed |
| US-20120259002-A1 | MOLECULE FOR TREATING AN INFLAMMATORY DISORDER | Acedemisch Ziekenhuis Leiden h.o.d.n. LUMC (NL) | 2012-10-11 | — | — | US | disclosed |
| WO-2011078672-A1 | MOLECULE FOR TREATING AN INFLAMMATORY DISORDER | PROSENSA TECHNOLOGIES B.V. (NL) | 2011-06-30 | — | — | WO | disclosed |